Barclays Upgrades IPSEN (OTCMKTS:IPSEY) to Hold

IPSEN (OTCMKTS:IPSEY) was upgraded by investment analysts at Barclays from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks reports.

Other equities research analysts have also issued research reports about the stock. Jefferies Financial Group lowered shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Finally, Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

IPSEN Price Performance

OTCMKTS IPSEY opened at $44.75 on Thursday. IPSEN has a 52 week low of $32.02 and a 52 week high of $51.10. The company has a fifty day moving average of $46.34 and a two-hundred day moving average of $46.70.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.